UY32235A - Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina - Google Patents
Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestinaInfo
- Publication number
- UY32235A UY32235A UY0001032235A UY32235A UY32235A UY 32235 A UY32235 A UY 32235A UY 0001032235 A UY0001032235 A UY 0001032235A UY 32235 A UY32235 A UY 32235A UY 32235 A UY32235 A UY 32235A
- Authority
- UY
- Uruguay
- Prior art keywords
- antigonist
- progestine
- strogen
- pharmaceutical
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008057230A DE102008057230A1 (de) | 2008-11-11 | 2008-11-11 | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32235A true UY32235A (es) | 2010-06-30 |
Family
ID=41606625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032235A UY32235A (es) | 2008-11-11 | 2009-11-10 | Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR074297A1 (de) |
DE (1) | DE102008057230A1 (de) |
PA (1) | PA8847901A1 (de) |
TW (1) | TW201022251A (de) |
UY (1) | UY32235A (de) |
WO (1) | WO2010054758A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2475366A1 (de) * | 2009-09-11 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Substituierte (heteroarylmethyl)-thiohydantoine als tumormittel |
US20130231292A1 (en) * | 2012-03-02 | 2013-09-05 | Wei Zhou | Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells |
WO2016004166A1 (en) * | 2014-07-02 | 2016-01-07 | Xavier University Of Louisiana | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
CN104370796B (zh) * | 2014-11-21 | 2016-09-14 | 扬子江药业集团有限公司 | 一种醋酸巴多昔芬多晶型b的制备方法 |
US20180200266A1 (en) * | 2015-07-14 | 2018-07-19 | Nobelpharma Co., Ltd. | ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
UA68365C2 (en) * | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
US6265393B1 (en) | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
DE60005693T2 (de) * | 1999-07-29 | 2004-07-29 | Eli Lilly And Co., Indianapolis | Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid |
DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
WO2003063859A1 (en) * | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
TW200307553A (en) * | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
JP4656939B2 (ja) | 2002-07-22 | 2011-03-23 | イーライ リリー アンド カンパニー | フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター |
US20080021003A1 (en) * | 2006-06-13 | 2008-01-24 | Vladimir Hanes | Extended step-down estrogen regimen |
-
2008
- 2008-11-11 DE DE102008057230A patent/DE102008057230A1/de not_active Withdrawn
-
2009
- 2009-10-31 WO PCT/EP2009/007801 patent/WO2010054758A1/en active Application Filing
- 2009-11-06 AR ARP090104296A patent/AR074297A1/es unknown
- 2009-11-09 PA PA20098847901A patent/PA8847901A1/es unknown
- 2009-11-10 UY UY0001032235A patent/UY32235A/es not_active Application Discontinuation
- 2009-11-11 TW TW098138262A patent/TW201022251A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DE102008057230A1 (de) | 2010-05-12 |
AR074297A1 (es) | 2011-01-05 |
PA8847901A1 (es) | 2010-06-28 |
TW201022251A (en) | 2010-06-16 |
WO2010054758A1 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110455A (es) | Derivados de indol como antagonistas del receptor crth2 | |
UY32819A (es) | Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2 | |
GT201500233A (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
GT201200147A (es) | Antagonistas de espiro-oxindol de mdm2 | |
CR20150296A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
ECSP15007420A (es) | Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
SV2010003687A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 | |
DOP2013000043A (es) | Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos | |
PA8849701A1 (es) | Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico | |
UY32235A (es) | Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina | |
CU20120175A7 (es) | Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos | |
CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
GT201300241A (es) | Composicion farmaceutica antihipertensiva | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
CO6531488A2 (es) | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1 | |
AR075260A1 (es) | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos | |
CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
CO6351799A2 (es) | Derivados de estratrieno que comprenden bioisosteros heterociclicos para el anillo fenolico a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181127 |